Tüdőrák: vizsgálatok itt: Lengyelország
116 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisFut, nem toborozA Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
- Where
- Gdansk, Koszalin, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06731907 · EU 2024-515772-12-00 - 3. fázisTaking peopleA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Where
- Lodz, Poznan, Przemyśl, Siedlce, Warsaw
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146 - 3. fázisFelfüggesztveSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Where
- Bialystok, Cracow, Gdansk, Katowice, Konin, Koszalin, Lodz, Lublin, Olsztyn, Poznan, Przemyśl, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 621 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712355 · EU 2024-515765-34-00 - 2/3. fázisNot yet taking people in LengyelországIZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
- Where
- Bydgoszcz, Gdynia, Lublin
- Életkor
- 18 év and over
- People
- 173 worldwide
- Run by
- Bristol-Myers Squibb Services Unlimited Company
See details and how to join2025-521908-22-00 - 1/2. fázisTaking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Gdansk, Warsaw
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - 3. fázisFelfüggesztveA Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Where
- Olsztyn, Rzeszów, Wrocław
- Életkor
- 18 év and over
- People
- 360 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00 - 2. fázisNot yet taking people in LengyelországA Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
- Where
- Bydgoszcz, Gdansk
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07871214 - 3. fázisTaking peopleSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Where
- Katowice, Kielce, Krakow, Lodz, Lublin, Opole, Radom, Tomaszow Mazowiecki, Wroclaw
- Életkor
- 18 év and over
- People
- 1410 worldwide
- Run by
- Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01 - 2. fázisNot yet taking people in LengyelországSymbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Where
- Gdansk, Lodz, Lublin, Wroclaw
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Pfizer
See details and how to joinNCT07489066 · EU 2025-524825-42-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Cracow, Gdansk, Lublin, Olsztyn, Poznan, Radom, Warsaw, Wieliszew, Wilkowice, Wroclaw
- Életkor
- 18 év and over
- People
- 282 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 - 2/3. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Cracow, Gdansk, Lublin, Poznan, Sosnowiec, Tomaszow Mazowiecki, Warsaw
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00 - 1. fázisTaking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Bydgoszcz, Gdansk, Otwock, Poznan, Wroclaw
- Életkor
- 18 év and over
- People
- 1394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - 2. fázisTaking peopleA Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
- Where
- Cracow, Lublin, Rzeszów, Torun, Warsaw
- Életkor
- 18 év and over
- People
- 243 worldwide
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT06907615 · EU 2025-523803-31-00 - 1/2. fázisNot yet taking people in LengyelországA Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- Where
- Gdansk, Koszalin, Warsaw
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00 - 3. fázisTaking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- Brzozów, Gdansk, Lublin, Szczecin
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00 - 1. fázisTaking peopleA Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
- Where
- Brzozów, Koszalin, Lublin, Olsztyn, Przemyśl
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391670 · EU 2025-521639-34-00 - 3. fázisTaking peopleClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Where
- Gdansk, Lodz, Lublin, Poznan, Skorzewo, Warsaw
- Életkor
- 18 év and over
- People
- 780 worldwide
- Run by
- Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00 - 2. fázisTaking peopleA Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Where
- Prabuty, Wieliszew
- Életkor
- 18 év and over
- People
- 182 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06855771 · EU 2024-519814-29-00 - 1/2. fázisTaking peopleA Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
- Where
- Otwock, Poznan, Przemyśl
- Életkor
- 18 év and over
- People
- 118 worldwide
- Run by
- MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07407933 - 3. fázisTaking peoplePhase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
- Where
- Gdansk, Warsaw
- Életkor
- 18 év and over
- People
- 168 worldwide
- Run by
- Amgen Inc.
See details and how to join2026-525489-23-00 - 3. fázisTaking peopleRoll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
- Where
- Bialystok, Bydgoszcz, Elblag, Lodz, Olsztyn, Szczecin, Warsaw
- Életkor
- 18 év and over
- People
- 87 worldwide
- Run by
- Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00 - 3. fázisTaking peopleStudy of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Lodz, Poznan, Rzeszów, Siedlce, Slupsk, Warsaw
- Életkor
- 18 év and over
- People
- 355 worldwide
- Run by
- Gilead Sciences Inc.
See details and how to join2024-515884-69-00 - 3. fázisFut, nem toborozPhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Where
- Bydgoszcz, Olsztyn, Poznan, Warsaw, Wilkowice
- Életkor
- 18 év and over
- People
- 582 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06350097 · EU 2023-509883-89-00 - 1/2. fázisTaking peopleA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Where
- Gdansk, Katowice, Lublin, Poznan
- Életkor
- 18 év and over
- People
- 594 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06892548 · EU 2024-520238-31-01 - 1. fázisTaking peopleStudy of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
- Where
- Gdansk, Gliwice, Warsaw
- Életkor
- 18 év to 99 év
- People
- 160 worldwide
- Run by
- Amgen
See details and how to joinNCT07531095 · EU 2025-522888-15-00